Sarepta Therapeutics, Inc. (SRPT) Earnings History
Profitable31 years of earnings data (1995–2025) · Positive TTM net income
Loading earnings history...
Sarepta Therapeutics, Inc. (SRPT) Earnings Overview
As of November 8, 2026, Sarepta Therapeutics, Inc. (SRPT) reported trailing twelve-month net income of $15M, reflecting -404.7% year-over-year growth. The company earned $0.14 per diluted share over the past four quarters, with a net profit margin of -32.5%.
Looking at the long-term picture, SRPT's historical earnings data spans multiple years. The company achieved its highest annual net income of $235M in fiscal 2024.
Sarepta Therapeutics, Inc. maintains positive profitability with a gross margin of 59.9%, operating margin of -29.9%, and net margin of -32.5%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including BMRN (-$19M net income, 10.8% margin), ALNY ($2.72B net income, 8.4% margin), RARE (-$524M net income, -85.4% margin), SRPT has room to improve margins relative to the peer group. Compare SRPT vs BMRN →
SRPT Earnings vs Peers
Earnings metrics vs comparable public companies
SRPT Historical Earnings Data (1995–2025)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$713M | -403.3% | -$658M | $-7.13 | -32.5% | -29.9% |
| 2024 | $235M | +143.9% | $218M | $2.34 | 12.4% | 11.5% |
| 2023 | -$536M | +23.8% | -$268M | $-5.80 | -43.1% | -21.5% |
| 2022 | -$703M | -68.0% | -$536M | $-8.03 | -75.4% | -57.5% |
| 2021 | -$419M | +24.4% | -$460M | $-5.15 | -59.7% | -65.5% |
| 2020 | -$554M | +22.5% | -$564M | $-7.11 | -102.6% | -104.5% |
| 2019 | -$715M | -97.6% | -$706M | $-9.71 | -187.8% | -185.3% |
| 2018 | -$362M | -614.0% | -$344M | $-5.46 | -120.2% | -114.1% |
| 2017 | -$51M | +81.0% | -$172M | $-0.86 | -32.8% | -111.0% |
| 2016 | -$267M | -21.5% | -$267M | $-5.49 | -4930.2% | -4920.3% |
| 2015 | -$220M | -62.0% | -$220M | $-5.20 | -17560.3% | -17572.5% |
| 2014 | -$136M | -21.3% | -$134M | $-3.39 | -1391.7% | -1371.2% |
| 2013 | -$112M | +7.7% | -$90M | $-3.31 | -787.6% | -635.0% |
| 2012 | -$121M | -5132.4% | -$30M | $-5.14 | -324.9% | -79.6% |
| 2011 | -$2M | +92.8% | -$36M | $-0.11 | -4.9% | -76.5% |
| 2010 | -$32M | -27.9% | -$21M | $-1.74 | -109.4% | -71.2% |
| 2009 | -$25M | -5.0% | -$16M | $-1.62 | -143.1% | -88.2% |
| 2008 | -$24M | +11.8% | -$27M | $-2.07 | -112.7% | -129.2% |
| 2007 | -$27M | +12.6% | -$33M | $-3.02 | -247.3% | -301.4% |
| 2006 | -$31M | -86.3% | -$33M | $-3.54 | -26951.8% | -28608.5% |
| 2005 | -$17M | +32.7% | -$18M | $-2.24 | -348.6% | -366.2% |
| 2004 | -$25M | -69.5% | -$25M | $-4.13 | -5756.1% | -5817.9% |
| 2003 | -$15M | +50.2% | -$19M | $-2.94 | -1507.1% | -1946.0% |
| 2002 | -$29M | -9.0% | -$25M | $-6.86 | -3508.6% | -3028.4% |
| 2001 | -$27M | -191.4% | -$15M | $-7.21 | -3813.2% | -2181.4% |
| 2000 | -$9M | -11.3% | -$10M | $-2.96 | -712.2% | -789.4% |
| 1999 | -$8M | +68.9% | -$8M | $-3.71 | -8300.0% | -8300.0% |
| 1998 | -$27M | -641.7% | -$8M | $-13.57 | -13350.0% | -3850.0% |
| 1997 | -$4M | -71.4% | -$4M | $-2.14 | -3600.0% | -3900.0% |
| 1996 | -$2M | +19.2% | -$2M | $-1.50 | -2100.0% | -2200.0% |
| 1995 | -$3M | - | -$3M | $-2.17 | -2600.0% | -2600.0% |
Download Data
Export SRPT earnings history in CSV or JSON format
Free sign-in required to download data
SRPT Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
What is SRPT earnings per share (EPS)?
SRPT trailing twelve-month (TTM) diluted EPS is $0.14, reflecting -404.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1995 to 2025 is available in the table on this page.
What is Sarepta Therapeutics, Inc.'s net income?
Sarepta Therapeutics, Inc. (SRPT) trailing twelve-month net income is $15M as of 2025. Earnings declined -404.7% year-over-year.
Is SRPT profitable?
Yes, SRPT is profitable with a TTM net income of $15M and a net profit margin of -32.5%.
What is SRPT's earnings growth rate?
SRPT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1995 to 2025.
What are SRPT's profit margins?
Sarepta Therapeutics, Inc. net profit margin is -32.5%, operating margin is -29.9%, and gross margin is +59.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is -53.5%.
Is SRPT growing earnings?
SRPT earnings are declining — EPS fell -404.7% year-over-year. TTM net income dropped to $15M. This contrasts with the 5-year CAGR of N/A.
What was SRPT's best earnings year?
Sarepta Therapeutics, Inc.'s highest annual net income on record is $235M, achieved in fiscal year 2024. Earnings history on this page spans 1995 to 2025 and includes all annual and quarterly figures.
What were SRPT's earnings last quarter?
SRPT's most recent reported quarter was Q3 2026. Net income was $-28M with diluted EPS of $-0.27. For a full breakdown of all quarters, see the quarterly earnings table on this page.